<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01317433</url>
  </required_header>
  <id_info>
    <org_study_id>CPP-450</org_study_id>
    <secondary_id>2010-019140-39</secondary_id>
    <nct_id>NCT01317433</nct_id>
  </id_info>
  <brief_title>Pre-emptive Cycline Treatment on Cetuximab Induced Skin Toxicity in Colorectal Cancer</brief_title>
  <acronym>SKINUX</acronym>
  <official_title>Pre-emptive Cycline Treatment on Cetuximab-induced Skin Toxicity in Patients With Metastatic Colorectal Cancer Treated With an Intensified FOLFIRI.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ICO Paul Papin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ICO Paul Papin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to test the role of cycline in the prevention of acne-like skin rash
      in metastatic colorectal patients treated with Cetuximab and intensified FOLFIRI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cetuximab, an Epidermal Growth Factor Receptor (EGFR) inhibitor, has shown to improve FOLFIRI
      efficacy up to 59.3% OR, in wild KRAS patients with advanced colorectal cancer. Skin toxicity
      occurs in 81.6% of patients as an acne-like skin rash developed on the face and the trunk
      inducing pain, decreasing quality of life and drug compliance. Over 104 patients enrolled in
      a phase II clinical trial sponsored by Center Paul Papin (NCT 00 559741), a grade &gt; or = 2
      cetuximab-acneiform rash occured in 51 patients (49%). In this trial Cetuximab was combined
      with a FOLFIRI intensified (5-FU intensification based on pharmacokinetics and
      pharmacogenetic studies of UGT1A1 status and DPD). Until now, no pre-emptive skin toxicity
      treatment with cycline has been demonstrated. Because of cycline's anti inflammatory
      properties and their use in inflammatory acne, cycline could prevent cetuximab-induced skin
      rash. In a randomized double-blind placebo-controlled phase III trial, Jatoi et al., failed
      to highlight any cycline effect on 61 patients. On the other hand, the STEPP study (95 pts)
      showed the impact of cycline to prevent panitumumab related skin toxicities. Our primary
      objective is to reduce the incidence of grade &gt; or = 2 acne-like skin rash by 30% with a 6
      weeks pre-emptive cycline treatment in patients with metastatic colorectal cancer undergoing
      cetuximab therapy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>reduction of Grade &gt; or = 2 acne-like skin rash by 30%</measure>
    <time_frame>6 weeks of pre-emptive cycline treatment</time_frame>
    <description>Skin tolerance will be assessed by a dermatologist at each cycle and NCI CTCAE v4.0 will be use for grading. Skin standardized photographs will be done at every cycle and a central double blind review wil be planned. Time to first occurence of grade &gt; or =2 skin toxicity will be assessed, and specificity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>skin tolerance assessment</measure>
    <time_frame>Until the end of Cetuximab treatment</time_frame>
    <description>Skin tolerance will be assessed weekly by a dermatologist from C1 to C3, and biweekly from C4 to C6 and NCI CTCAE v4.0 will be use for grading. All grade &gt; or = 1 skin and hair/nails toxicities will be reported. Time to most severe skin toxicity will be assessed. Quality of life questionnaires with a skin interest (DLQI) will be evaluated at baseline and at each cycle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non skin toxicities assessment</measure>
    <time_frame>Until the end of chemotherapy treatment</time_frame>
    <description>For non skin toxicities, only grade &gt; or = 3 will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy Objective Response (OR) assessment</measure>
    <time_frame>Until the end of chemotherapy treatment</time_frame>
    <description>Efficacy OR (Complete Response + Partial Response) will be assessed by the investigator with usual tumoral evaluation. Tumoral evaluation will be assessed with the same exam throughout the trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological correlation with response and survival</measure>
    <time_frame>3 years</time_frame>
    <description>Biological correlation with response and survival will be tested for KRAS, BRAF, PI3K,PTEN, epiregulin, amphiregulin, IGF1, Syndecan-1, UBE2C, EGFR polymorphism.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To Progression and Overall Survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resectability rate</measure>
    <time_frame>Until the end of chemotherapy treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Colorectal Cancer Metastatic</condition>
  <condition>Skin Toxicity</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intensified FOLFIRI plus Cetuximab + Doxycycline 100 mg daily per os to start 7 days before Cetuximab for 6 weeks + skin moisturizers (Dexeryl), sun protection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Intensified FOLFIRI plus Cetuximab + skin moisturizers (Dexeryl), sun protection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <description>Doxycycline 100 mg daily per os to start 7 days before Cetuximab for 6 weeks.</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>500 mg/m² IV infusion of 60 minutes every 15 days</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced or metastatic colorectal cancer, histologically confirmed, first or second
             metastatic line

          -  K-RAS wild-type

          -  Adjuvant prior chemotherapy allowed provided that all toxicities are grade &lt; or = 1
             (excepted alopecia and neuropathy)

          -  Age between 18 and 80 years

          -  WHO Performance Status &lt; or = 2

          -  Complete initial assessment before first treatment administration for imaging and
             pharmacogenetic, within 15 days for biology, and within 7 days for clinical
             examination.

          -  Haematologic and hepatic parameters : neutrophils &gt; or = 1500 /mm3, platelets &gt; or =
             100000/mm3, Total bilirubin &lt; or 2 x ULN, AST and ALT &lt; or = 3 x ULN, APL &lt; or = 5 x
             ULN

          -  Absence of total dihydropyrimidine dehydrogenase deficiency

          -  Patient able to comply with study requirements

          -  Signed written informed consent

        Exclusion Criteria:

          -  History or presence of an other cancer, excepted cutaneous cancer (basocellular
             carcinoma), in situ cancer of the cervix or breast cancer curatively treated

          -  Any other concomitant anti-cancer therapy

          -  Prior anti EGFR therapy, anti angiogenic therapy is allowed

          -  Prior cyclines hypersensitivity

          -  Treatment with cyclines within 7 days before randomization

          -  Presence of a rash at randomization time

          -  Symptomatic or uncontrolled ventral nervous system metastases

          -  Total dihydropyrimidine dehydrogenase deficiency

          -  No recovery of any toxicity Grade &lt; or = 1 related to a past anticancerous treatment
             excepted for alopecia and neuropathy

          -  Active inflammatory bowel disease or other bowel

          -  Significant serious pathology or any unstable medical condition (cardiac pathology
             uncontrolled, myocardial infarction within 6 months before enrollment, systemic active
             uncontrolled infection)

          -  atropine contra-indication

          -  any investigational agent without marketing authorization within 4 weeks before
             enrollment

          -  Patient who is pregnant or breast feeding

          -  Woman or man of childbearing potential not consenting to use adequate contraceptive
             precautions during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Capitain, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICO Paul Papin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Virginie Berger, MD, PhD</last_name>
    <phone>33 2 41 35 27 34</phone>
    <email>virginie.berger@ico.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jessy Delaye, M Sc</last_name>
    <phone>33 2 41 35 29 31</phone>
    <email>jessy.delaye@ico.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ICO Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginie Berger, MD, PhD</last_name>
      <email>virginie.berger@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier Capitain, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe Borg, MD</last_name>
      <email>christophe.borg@efs.sante.fr</email>
    </contact>
    <investigator>
      <last_name>Christophe Borg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Philippe Metges, MD</last_name>
      <email>jean-philippe.metges@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Philippe Metges, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Cholet</city>
        <zip>49325</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>You Heng Lam, MD</last_name>
      <email>you.lam@ch-cholet.fr</email>
    </contact>
    <investigator>
      <last_name>You Heng Lam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Départemental Les Oudairies</name>
      <address>
        <city>La Roche Sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roger Faroux, MD</last_name>
      <email>roger.faroux@chd-vendee.fr</email>
    </contact>
    <investigator>
      <last_name>Roger Faroux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://www.centrepaulpapin.org/</url>
    <description>Sponsor Information</description>
  </link>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2011</study_first_submitted>
  <study_first_submitted_qc>March 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2011</study_first_posted>
  <last_update_submitted>February 28, 2012</last_update_submitted>
  <last_update_submitted_qc>February 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 29, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic Colorectal Cancer</keyword>
  <keyword>K-RAS wild-type</keyword>
  <keyword>FOLFIRI</keyword>
  <keyword>Cetuximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

